This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rancourt, C. Articles by Curiel, D. T. Search for Related Content PubMed PubMed Citation Articles by Rancourt, C. Articles by Curiel, D. T.

Interleukin-6 Modulated Conditionally Replicative Adenovirus as an Antitumor/Cytotoxic Agent for Cancer Therapy¹

Gene Therapy Program [C. R., A. P., J. G-N., M. W., D. T. C.] and Departments of Obstetrics and Gynecology [R. D. A.], Pathology, Cell Biology, and Surgery [G. P. S.], and Cell Biology [G. M. F., S. A. J.], University of Alabama at Birmingham, Birmingham, Alabama 35294, and Département de Microbiologie et Infectiologie, Faculté de Médecine, Université de Sherbrooke, Québec, Canada, J1H 5N4 [C. R., A. P.]

In this study, we report that an interleukin-6 (IL-6)-inducible E1A-substituting activity can be exploited for the production of infectious adenoviral particles during infection with the E1A-deleted adenovirus (Ad) Ad5dl312. The basal level of complementation can be increased by 1.5 log by induction of the HepG2 cells with recombinant human IL-6. Additionally, the IL-6-inducible E1A-substituting activity can complement E1A deletion in other cancer cell lines to render them Ad producer cells on induction with recombinant human IL-6, although the efficiency of complementation varies between cell lines. Ad5dl312 can replicate in, produce cytotoxic effect, and kill human tumor cells without addition of exogenous IL-6 in the context of tumor cells possessing an IL-6 autocrine arc, such as ovarian tumor cells. In contrast, normal human mesothelial cells isolated from normal human peritoneum lining do not support replication of Ad5dl312, even in the presence of exogenous IL-6. These results suggest that Ad5dl312 could be used as a cytotoxic agent to selectively kill tumor cells responsive to or possessing an IL-6 autocrine arc.

This article has been cited by other articles:

				K. M. Bernt, D. S. Steinwaerder, S. Ni, Z.-Y. Li, S. R. Roffler, and A. Lieber Enzyme-activated Prodrug Therapy Enhances Tumor-specific Replication of Adenovirus Vectors Cancer Res., November 1, 2002; 62(21): 6089 - 6098. [Abstract] [Full Text] [PDF]

				K. Bernt, M. Liang, X. Ye, S. Ni, Z.-Y. Li, S. L. Ye, F. Hu, and A. Lieber A New Type of Adenovirus Vector That Utilizes Homologous Recombination To Achieve Tumor-Specific Replication J. Virol., October 2, 2002; 76(21): 10994 - 11002. [Abstract] [Full Text] [PDF]

				W. C. Russell Update on adenovirus and its vectors J. Gen. Virol., November 1, 2000; 81(11): 2573 - 2604. [Full Text]

				D. T. Curiel The Development of Conditionally Replicative Adenoviruses for Cancer Therapy Clin. Cancer Res., September 1, 2000; 6(9): 3395 - 3399. [Abstract] [Full Text]